Insmed Incorporated

INSMleader

Insmed is a rare-disease biopharmaceutical company commercializing ARIKAYCE for MAC lung disease, with brensocatib (bronchiectasis) representing a potential $2B+ revenue opportunity in 2025.

⇄ Compare

Produk & Pendapatan

Pangsa Pendapatan Produk

Komposisi Pendapatan ($350M)

Data statis (memuat keuangan langsung…)

ARIKAYCE (US + ex-US) (100%)

Komposisi segmen dan pelanggan utama

Detail produk

ARIKAYCE (MAC lung disease)65%

Inhaled amikacin liposome inhalation suspension — first FDA-approved drug for refractory MAC lung disease, a rare NTM infection.

Brensocatib (bronchiectasis)35%

DPP1 inhibitor in Phase III ASPEN trial for non-CF bronchiectasis — potential blockbuster for 200k+ US patients.

Hubungan Rantai Pasok

Mitra

astrazeneca

Japan ARIKAYCE co-promotion

Dampak: moderate

Konteks makro dan pasar

헬스케어Berita sektor

메디케어 수가 압박 vs AI 진단 효율화 — 선별적 접근 필요

미국 헬스케어 지출 (2026E)

$4.8T

AI 진단 정확도 개선

+23% vs 기존

UNH 의료손해율

87.3%

약가 협상 대상 의약품

20종 (IRA)

Katalis mendatang

◆CMS 메디케어 최종 수가 발표 (2026.Q2)◆UNH/HUM/CVS Q1 실적 (2026.04)◆IRA 약가 협상 2차 품목 공개

Berita terkini

Memuat berita...

Analisis AI

Klik "Dapatkan Analisis AI" untuk analisis rantai pasok Insmed Incorporated.

Info Perusahaan

Kantor Pusat

Bridgewater, New Jersey, USA

Didirikan

1999

Karyawan

1,500

Situs Web

insmed.com

Gambaran umum sektor — 헬스케어

Berita sektor